Makabayi-Mugabe, Rita
Musaazi, Joseph
Zawedde-Muyanja, Stella
Kizito, Enock
Fatta, Katherine
Namwanje-Kaweesi, Hellen
Turyahabwe, Stavia
Nkolo, Abel
Funding for this research was provided by:
United States Agency for International Development (USAID) through Defeat TB Project (USAID Cooperative Agreement Number AID-617-A-17-00003, USAID Cooperative Agreement Number AID-617-A-17-00003, USAID Cooperative Agreement Number AID-617-A-17-00003, USAID Cooperative Agreement Number AID-617-A-17-00003, USAID Cooperative Agreement Number AID-617-A-17-00003, USAID Cooperative Agreement Number AID-617-A-17-00003, USAID Cooperative Agreement Number AID-617-A-17-00003)
Article History
Received: 18 May 2023
Accepted: 5 October 2023
First Online: 13 November 2023
Declarations
:
: This research was performed in accordance with the Declaration of Helsinki guidelines. It was approved by the Joint Clinical Research Centre (JC1519) Institutional Review Board (IRB), and by the Uganda National Council of Science and Technology (HS2684) prior to study conduct. Administrative permission to collect this data were provided by the Ministry of Health- National TB and Leprosy Program and by respective study sites. Prior to interview commencement, written informed consent was voluntarily obtained from all participants. Confidentiality of patients was ensured by using study identification numbers and data storage protection procedures.
: Not applicable.
: The authors declare no competing interests.